Andrew Mendelsohn

Andrew Mendelsohn has a diverse work experience spanning over several years. Andrew currently holds the position of Chief Scientific Officer at Panorama Research Inc. since February 2022. In addition to this role, they also serve as a Senior Scientific Advisor at Corsalex, which they joined in May 2022.

Prior to these positions, Andrew was involved in various entrepreneurial ventures. Andrew co-founded Eumentis Therapeutics Inc. in October 2019, where they served as a Co-Founder. Andrew also played a key role in establishing Regenerative Sciences Institute in November 2005, where they held the position of Director of Research and Founder.

Furthermore, Andrew co-founded Next Interactions in January 2016 and held the position of Co-founder. Andrew also served as the Director of Molecular Biology at Panorama Research Institute from October 2005 to February 2022.

In 2013, Andrew Mendelsohn co-founded Wntgen LLC, a company specializing in developing novel therapies for aging-related diseases. Andrew held the role of Co-Founder until June 2019.

Before their entrepreneurial endeavors, Andrew gained valuable research experience. Andrew worked as a Senior Research Fellow at Molecular Sciences Institute from January 1998 to September 2004. Prior to that, they served as a Research Fellow at Massachusetts General Hospital from 1991 to 1997.

Andrew Mendelsohn completed their Bachelor of Arts (BA) degree in Biophysics and Natural Science at the University of Pennsylvania from 1976 to 1981. Later, they pursued their PhD in Molecular, Cell Biology, and Biochemistry at Brown University and completed it in 1991.